EI

270.6

-0.11%↓

MRK1

107.55

+0.99%↑

SAN

79.42

+0.88%↑

SHL.DE

47.3

-0.65%↓

ARGX

627

-0.73%↓

EI

270.6

-0.11%↓

MRK1

107.55

+0.99%↑

SAN

79.42

+0.88%↑

SHL.DE

47.3

-0.65%↓

ARGX

627

-0.73%↓

EI

270.6

-0.11%↓

MRK1

107.55

+0.99%↑

SAN

79.42

+0.88%↑

SHL.DE

47.3

-0.65%↓

ARGX

627

-0.73%↓

EI

270.6

-0.11%↓

MRK1

107.55

+0.99%↑

SAN

79.42

+0.88%↑

SHL.DE

47.3

-0.65%↓

ARGX

627

-0.73%↓

EI

270.6

-0.11%↓

MRK1

107.55

+0.99%↑

SAN

79.42

+0.88%↑

SHL.DE

47.3

-0.65%↓

ARGX

627

-0.73%↓

Search

UCB SA

Geschlossen

BrancheGesundheitswesen

203.7 -0.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

202.2

Max

205.2

Schlüsselkennzahlen

By Trading Economics

Einkommen

-382M

475M

Verkäufe

126M

3.5B

KGV

Branchendurchschnitt

29.956

35.293

Dividendenrendite

0.67

Gewinnspanne

13.622

Angestellte

8,600

EBITDA

-341M

1B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.23% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.67%

3.07%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

5B

39B

Vorheriger Eröffnungskurs

203.75

Vorheriger Schlusskurs

203.7

Nachrichtenstimmung

By Acuity

45%

55%

174 / 371 Ranking in Healthcare

UCB SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Juli 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

Peer-Vergleich

Kursveränderung

UCB SA Prognose

Kursziel

By TipRanks

19.23% Vorteil

12-Monats-Prognose

Durchschnitt 94.86 EUR  19.23%

Hoch 125 EUR

Tief 74 EUR

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für UCB SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

1

Halten

2

Sell

Stimmung

By Acuity

174 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
help-icon Live chat